Bellerophon to present at the h.c. wainwright virtual bioconnect 2021 conference

Warren, n.j., jan. 04, 2021 (globe newswire) -- bellerophon therapeutics, inc. (nasdaq: blph) (“bellerophon” or the “company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that fabian tenenbaum, chief executive officer, will present a corporate overview at the h.c. wainwright virtual bioconnect 2021 conference, being held january 11-14, 2021.
BLPH Ratings Summary
BLPH Quant Ranking